Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQ2AIJ)

Drug Name
Lestaurtinib Drug Info
Synonyms A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
126565
ChEBI ID
CHEMBL603469
CAS Number
CAS 111358-88-4
TTD Drug ID
D0V9WF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.57 0.00e+0 113/158 (71.52%) RPL29;MRPS16;RPS5;...
Oxidative phosphorylation 2.01 0.00e+0 93/133 (69.92%) ATP5MC2;NDUFB1;NDUFA1;...
Valine, leucine and isoleucine degradation 1.88 4.79e-3 42/48 (87.5%) ALDH6A1;ABAT;HADHA;...
Butanoate metabolism 1.87 8.98e-3 23/28 (82.14%) ABAT;HADHA;ACAT1;...
Glyoxylate and dicarboxylate metabolism 1.80 2.01e-2 23/30 (76.67%) AMT;GLUL;ACAT1;...
Glycine, serine and threonine metabolism 1.75 3.11e-2 31/40 (77.5%) AMT;PIPOX;GAMT;...
TNF signaling pathway -1.73 4.98e-2 103/112 (91.96%) PIK3CB;MAP2K3;CFLAR;...
Fluid shear stress and atherosclerosis -1.76 4.98e-2 123/139 (88.49%) SDC1;ACVR1;MAPK13;...
ECM-receptor interaction -1.81 2.18e-2 80/88 (90.91%) COL1A2;CD36;ITGA2;...
Amino sugar and nucleotide sugar metabolism -1.90 8.29e-3 38/48 (79.17%) CHIA;FPGT;GFPT1;...
IL-17 signaling pathway -2.09 0.00e+0 84/94 (89.36%) TRAF2;MAPK13;CCL17;...
Proteasome -2.22 0.00e+0 44/46 (95.65%) PSMD3;PSMB6;PSME3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.05uM - 4uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.03uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H